Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
coramitug
- Development stage
- Phase 3
- Lead developer
- Novo Nordisk
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Coramitug (formerly PRX004 or NNC6019-0001) is a humanized monoclonal antibody designed to treat transthyretin amyloidosis (ATTR), specifically transthyretin amyloid cardiomyopathy (ATTR-CM). Developed by Novo Nordisk following its acquisition from Prothena, the antibody specifically targets and binds to misfolded, pathogenic forms of the transthyretin (TTR) protein. By binding to these misfolded proteins and amyloid deposits, coramitug promotes their clearance through antibody-mediated phagocytosis. Importantly, it is engineered to avoid binding to the native, functional tetrameric form of TTR, thereby preserving its normal physiological function. It is currently being evaluated in the Phase 3 CLEOPATTRA trial for its impact on cardiovascular outcomes in patients with ATTR-CM.
- Brand names
- Coramitug
- Other names
- coramitug
02
Targets
TTR amyloid fibril (Transthyretin amyloid fibril)TTR (Transthyretin)
Beyond the preview
Go deeper on coramitug.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on coramitug.